FDA Approves Long-Acting HIV Prevention Drug

The FDA approved Gilead Sciences’ long-acting injectable lenacapavir for HIV prevention. Administered twice yearly, it offers an alternative to daily PrEP pills and may help address adherence challenges and stigma. The article reports no financial figures or stock-price impact.